Gujarat FDCA: 202 cases of ceiling price violations referred to NPPA during lockdown period

202 cases of ceiling price violations has been referred by the Gujarat Food and Drug Control Administration (FDCA) to the National Pharmaceutical Pricing Authority (NPPA) during the lockdown period of March, April and May through its Price Monitoring and Research Unit (PMRU).

PMRU operations has been started by the state drug regulators in all the 33 districts of the state from October 1, 2019 onwards to track price violations by the pharma companies. The systematic form is the part of NPPA policy to keep an oversight on pharma companies for any kind of drug price violation.

Gujarat FDCA Commissioner Dr H G Koshia said that “Having manned with information technology (IT) staff, the PMRU which is led by a project co-ordinator having a Pharm D qualification is assisted by three field investigators to bring in insights about price violations in real time. At present NPPA is reviewing the cases of violations and will get back with details of the amount to be recovered from the offending companies.”
NPPA has recently set up PMRU in Jammu & Kashmir Union Territory (UT). Till date, PMRUs have been established in various states- Gujarat like Kerala, Odisha, Rajasthan, Punjab, Haryana, Nagaland and Tripura with the latest entrant being Uttar Pradesh (UP). NPPA has recently set up PMRU in Jammu & Kashmir Union Territory (UT).

According to the notification stated, “Each unit will function under the direct supervision of the SDC. PMRUs will be the key collaborating partners of NPPA, with information-gathering mechanism at the grassroots level. PMRUs will also ensure that the benefits of DPCO percolate down to the grassroots level. The central funding will be for an initial period of five years subject to a mid-term review.”

As of now, consent has been given by 21 states for formation of PMRU. These are Assam, Gujarat, Haryana, Maharashtra, Manipur, Odisha, Punjab, Tripura, Mizoram, Rajasthan, Chhattisgarh, Bihar, Nagaland, Goa, Delhi, Tamil Nadu, Madhya Pradesh, Uttarakhand, Puducherry, Andhra Pradesh and Kerala.

  • Related Posts

    ‘Import of Refurbished Medical Devices’ Lobby has reared its Ugly Head

    Domestic Medical Device Leaders cry foul against move to do away with Policy Restrictions New Delhi:  The union government mandarins seem to be at it again, diametrically opposed to Prime…

    Indigenous Robotic Surgery is Mantra for Accessible Cancer Care in India

    Best in Class ‘Made in India’ Surgical Robot is proving Best Bet New Delhi: ‘Made in India’ best in class surgical robot SSiMantra is proving godsend for cancer patients in…

    Leave a Reply

    Your email address will not be published. Required fields are marked *

    You Missed

    Medical Negligence and Quackery Rampant: 9-Year-Old Dies from Wrong Injection, Pregnant Woman Succumbs to Quack Treatment, Raids Uncover Illegal Practices Across MP, Haryana, UP & Chhattisgarh

    Medical Negligence and Quackery Rampant: 9-Year-Old Dies from Wrong Injection, Pregnant Woman Succumbs to Quack Treatment, Raids Uncover Illegal Practices Across MP, Haryana, UP & Chhattisgarh

    Drug Diversion Epidemic Sweeps India: Absence of Track-and-Trace System, overly Codeine Allotments, and Regulatory Apathy Fuel Misuse of Narcotic Syrups and Tablets

    Drug Diversion Epidemic Sweeps India: Absence of Track-and-Trace System, overly Codeine Allotments, and Regulatory Apathy Fuel Misuse of Narcotic Syrups and Tablets

    Multi-State Supply Chain of Fake RituxiRel and Alburel Injections Exposed Amid Health Risks

    Multi-State Supply Chain of Fake RituxiRel and Alburel Injections Exposed Amid Health Risks

    TN, Karnataka, Rajasthan declare highest number of NSQs in January

    TN, Karnataka, Rajasthan declare highest number of NSQs in January

    Centre reorganises CDSCO Zone Baddi amid Drug Quality Concerns

    Centre reorganises CDSCO Zone Baddi amid Drug Quality Concerns

    CDSCO modifies norms for testing permissions to speed up drug approvals

    CDSCO modifies norms for testing permissions to speed up drug approvals